新京报贝壳财经讯 2月4日，信达生物公告，于2025年全年，公司实现总产品收入约人民币119亿元，同 比保持约45%的强劲增长态势。2025年第四季度，公司实现总产品收入约人民币33亿元，同比增长超 60%以上。 ...

Core Insights - The company achieved total product revenue of approximately RMB 11.9 billion in 2025, marking a strong year-on-year growth of about 45% [1] - In Q4 2025, the company recorded total product revenue of approximately RMB 3.3 billion, with a year-on-year increase of over 60%, driven by the inclusion of six new drugs in the 2026 National Medical Insurance Directory [1] Group 1 - 2025 marked a milestone year for the company as product revenue surpassed RMB 10 billion, reflecting the successful implementation of its "dual-driven and global innovation" strategy [2] - The company has expanded its oncology product portfolio to 13 products, with core products like Dabrushe (sintilimab injection) showing steady growth and new products contributing significantly to revenue [2] - The company has successfully entered the chronic disease commercialization sector, leveraging unmet needs and strong product competitiveness to drive growth [2] Group 2 - The company’s innovative pipeline focuses on next-generation immunotherapy (IO) and antibody-drug conjugates (ADC), along with developments in metabolic and cardiovascular (CVM), autoimmune, and ophthalmology fields, which are making significant progress [3] - The company aims to become an internationally leading biopharmaceutical company, supported by its global clinical development efforts [3]

Core Viewpoint - The completion of the H-share full circulation by Fuhong Hanlin marks a significant step in the company's equity structure and capital operations, enhancing liquidity and governance standards while supporting its global strategy and innovation efforts [1] Group 1: H-share Full Circulation - A total of 183 million non-listed shares have been converted into H-shares, which will start trading on the Hong Kong Stock Exchange on February 5, 2026 [1] - After the full circulation, the total number of H-shares will increase to 346 million [1] - The full circulation is expected to attract more international investors, benefiting the long-term development of the company and its shareholders [1] Group 2: Product Portfolio and Market Presence - Fuhong Hanlin has 10 products approved for sale in over 60 markets globally [1] - The company has achieved significant milestones in major biopharmaceutical markets, with 4 products receiving FDA approval and 4 products obtaining EMA authorization [1] - The company has a diversified pipeline with over 50 early-stage molecules, demonstrating its commitment to high-quality research and development aligned with international standards [1]

与此同时，本公司全球创新布局持续突破，以新一代免疫疗法(IO)、抗体偶联药物(ADC)为核心的肿瘤 创新管线，以及新一代代谢及心血管(CVM)、自身免疫及眼科领域创新管线的全球临床开发，正逐步取 得关键性进展，持续打开本公司成长空间，助力本公司稳步迈向"成为国际一流的生物制药公司"的核心 愿景。 2025年是本公司产品收入首次突破百亿人民币的里程碑之年，标志着本公司"双轮驱动与全球创新"战略 的成功落地及卓越成效。本公司在肿瘤治疗领域持续巩固领先地位，肿瘤产品组合已拓展至13款，协同 效应日益凸显;其中达伯舒®(信迪利单抗注射液)等核心产品保持稳健增长，多款新产品亦贡献显著收入 增量。与此同时，本公司成功拓展慢病商业化领域并取得亮眼成果，依托慢病领域广阔的未被满足需 求、本公司强劲的产品竞争力及科学高效的商业化策略，综合产品线展现出强劲的增长动能。信尔美 ®(玛仕度肽注射液)、信必乐®(托莱西单抗注射液)和信必敏®(替妥尤单抗N01注射液)的市场放量持续加 速，均已成为本公司收入增长的关键新兴动力。此外，综合产品线另一重要产品信美悦®(匹康奇拜单 抗注射液)亦于2025年年底顺利批准上市。 2025年的产品业 ...

Core Viewpoint - The completion of H-share full circulation by Fuhong Hanlin marks a significant step in the company's equity structure and capital operations, enhancing liquidity and governance standards while supporting its global strategy and innovation efforts [1] Group 1: H-share Full Circulation - A total of 183 million non-listed shares were converted into H-shares, which will begin trading on the Hong Kong Stock Exchange on February 5, 2026 [1] - Following the full circulation, the total number of H-shares will increase to 346 million [1] - The full circulation is expected to attract more international investors, benefiting the long-term development and shareholder interests of the company [1] Group 2: Product Portfolio and Market Presence - Fuhong Hanlin has 10 products approved for sale in over 60 markets globally [1] - The company has achieved significant milestones in major biopharmaceutical markets, with 4 products receiving FDA approval and 4 products obtaining EMA authorization [1] - The company has a diversified pipeline with over 50 early-stage molecules, demonstrating its commitment to high-quality research and development aligned with international standards [1]

Core Insights - The company achieved total product revenue of approximately RMB 11.9 billion in 2025, marking a strong year-on-year growth of about 45% [1] - In Q4 2025, the company recorded total product revenue of approximately RMB 3.3 billion, with a year-on-year increase of over 60%, driven by the inclusion of six new drugs in the 2026 National Medical Insurance Directory [1] Group 1 - 2025 marked a milestone year for the company as product revenue surpassed RMB 10 billion, reflecting the successful implementation of its "dual-driven and global innovation" strategy [2] - The company has strengthened its leading position in the oncology treatment sector, expanding its oncology product portfolio to 13 products, with core products like Darbeshou (Sintilimab injection) showing steady growth [2] - The company has successfully ventured into the chronic disease commercialization field, leveraging unmet needs and strong product competitiveness to drive growth, with key products like Xin'ermei (Masitide injection) and Xinbile (Torecilizumab injection) becoming significant revenue contributors [2] Group 2 - The company's global innovation strategy continues to make breakthroughs, focusing on next-generation immunotherapy (IO) and antibody-drug conjugates (ADC) in oncology, as well as innovations in metabolism, cardiovascular, autoimmune, and ophthalmology fields [3] - The company aims to become an internationally leading biopharmaceutical company, supported by its ongoing clinical development and strategic advantages in flexible layout and efficient execution [3]

Core Viewpoint - The completion of the H-share full circulation marks a significant step for the company in terms of equity structure and capital operations, enhancing liquidity and governance while supporting its global strategy and innovation efforts [1] Group 1: H-share Full Circulation - The company announced the conversion of 182,645,856 non-listed shares into H-shares, which will start trading on February 5, 2026, increasing the total number of H-shares to 346,074,397 [1] - This move is expected to expand the liquidity of the company's shares listed in Hong Kong and improve market pricing effectiveness and fairness [1] Group 2: Financial Performance and Strategic Development - The company became the first Hong Kong-listed innovative pharmaceutical company to achieve full-year profitability in 2023, driven by product sales [1] - The stable cash flow generated from biosimilars will support ongoing innovation and research and development, as the company transitions into a "Globalization 2.0" development phase characterized by capability building and innovation [1]

Core Viewpoint - Palin Biopharma (000403) announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., received the approval notice for the marketing registration of human coagulation factor IX from the National Medical Products Administration [1] Group 1 - The approved drug, human coagulation factor IX, is indicated for the treatment of patients with congenital factor IX deficiency, specifically those with hemophilia B, or patients with low levels of factor IX due to other reasons [1] - The drug is expected to significantly increase the levels of human coagulation factor IX in the blood, thereby achieving the goal of preventing and treating bleeding [1]

Core Viewpoint - The report emphasizes the commitment of Zhangqiu District to high-quality development through the "Project Empowerment Year," aiming for a GDP growth of approximately 5.3% by 2026 while focusing on four key positioning areas: "Qilu Technology Innovation Manufacturing High Ground," "Longshan Spring Cultural Tourism City," "Jinan School-City Collaborative Integration Demonstration Zone," and "Modernized Strong District in Jinan Metropolitan Area" [2][3][4]. Economic Growth Targets - The main expected economic development targets for 2026 include a GDP growth of around 5.3%, a general public budget revenue increase of 3%, and an industrial added value growth of 7.5% [4]. - The social retail sales of consumer goods are projected to grow by 3.5%, with urban residents' per capita disposable income growth synchronized with economic growth, while rural residents' income growth is expected to exceed that of urban residents [4]. Investment and Consumption Strategies - The report highlights the importance of expanding domestic demand and enhancing economic recovery through initiatives like promoting large consumer goods replacement and expanding urban and rural consumption markets [5]. - Investment structure optimization is emphasized, with a focus on industrial investment, high-tech investment, and new investment, aiming to increase the share of private investment by 4 percentage points [5]. Industrial Development and Upgrading - Zhangqiu District aims to strengthen the real economy by promoting key projects in the main industrial chain, including new energy and intelligent manufacturing [6]. - The district plans to enhance the digital economy and logistics industries, with a target of reaching 210 service enterprises and a revenue of over 11.5 billion yuan in the service sector [6]. Innovation and Talent Development - The report stresses the creation of an innovation and entrepreneurship ecosystem, focusing on the construction of innovation clusters around universities and the establishment of new research platforms [7]. - It aims to cultivate a talent pool by introducing and training over 15 high-level talents and incubating more than 10 quality talent projects [7]. Rural Revitalization Initiatives - Rural revitalization is prioritized, with plans to create high-standard farmland and develop modern facility agriculture, aiming for stable production capacities in various agricultural sectors [8]. - The district also plans to enhance rural living conditions and increase farmers' income through asset utilization reforms and training programs [8]. Urban Development and Public Services - The report outlines urban governance and ecological protection efforts, including infrastructure projects and environmental management to improve living standards [9]. - It emphasizes the importance of social security and public service equalization, with initiatives to enhance education and healthcare services [10].

格隆汇2月4日丨复宏汉霖(02696.HK)发布公告，合计约1.83亿股非上市股已于2026年2月4日完成转换为 H股，该等转换H股将于2026年2月5日上午九时正开始于联交所上市。 ...